{"id":"https://openalex.org/W2987520201","doi":"https://doi.org/10.1182/blood-2019-123665","title":"Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na\u00efve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)","display_name":"Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na\u00efve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2987520201","doi":"https://doi.org/10.1182/blood-2019-123665","mag":"2987520201"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-123665","doi":"https://doi.org/10.1182/blood-2019-123665","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-123665","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016570475","display_name":"Jennifer R. Brown","orcid":"https://orcid.org/0000-0003-2040-4961","observed_orcids":["https://orcid.org/0000-0003-2040-4961"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer R. Brown","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030989742","display_name":"Julie E Chang","orcid":"https://orcid.org/0000-0002-1255-1163","observed_orcids":["https://orcid.org/0000-0002-1255-1163"]},"institutions":[{"id":"https://openalex.org/I135310074","display_name":"University of Wisconsin\u2013Madison","ror":"https://ror.org/01y2jtd41","country_code":"US","type":"education","lineage":["https://openalex.org/I135310074"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie E Chang","raw_affiliation_strings":["University of Wisconsin School of Medicine and Public Health, Madison, WI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Wisconsin School of Medicine and Public Health, Madison, WI","institution_ids":["https://openalex.org/I135310074"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079663967","display_name":"Shuo Ma","orcid":"https://orcid.org/0000-0002-6139-5486","observed_orcids":["https://orcid.org/0000-0002-6139-5486"]},"institutions":[{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shuo Ma","raw_affiliation_strings":["Robert H. Lurie Comprehensive Cancer Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Robert H. Lurie Comprehensive Cancer Center, Chicago, IL","institution_ids":["https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112879176","display_name":"Juliana M.L. Biondo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Juliana M L Biondo","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113849494","display_name":"Yong Mun","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yong Mun","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025092706","display_name":"Madlaina Breuleux","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Madlaina Breuleux","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William G. Wierda","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"4320","last_page":"4320"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.8939999938011169},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9660000205039978},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.7269999980926514},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.753000020980835},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.8410000205039978},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":0.796999990940094},{"id":"https://openalex.org/keywords/btk-inhibitor-resistance","display_name":"BTK inhibitor resistance","score":0.49399998784065247},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.5680000185966492},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7480000257492065},{"id":"https://openalex.org/keywords/treatment-sequencing","display_name":"treatment sequencing","score":0.5130000114440918},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.47999998927116394},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.4399999976158142}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.866855800151825},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8020213842391968},{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.7730332016944885},{"id":"https://openalex.org/C9583187","wikidata":"https://www.wikidata.org/wiki/Q7919510","display_name":"Ven","level":2,"score":0.6265274882316589},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.601753294467926},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5617062449455261},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5233627557754517},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.4203532636165619},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.407524973154068},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3782614767551422},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2516047954559326},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.16180309653282166},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.14499709010124207},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-123665","doi":"https://doi.org/10.1182/blood-2019-123665","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-123665","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2910431445","https://openalex.org/W2921140763","https://openalex.org/W2952375224","https://openalex.org/W2985060532","https://openalex.org/W3097908862","https://openalex.org/W4310093475","https://openalex.org/W2900949333","https://openalex.org/W4389231300","https://openalex.org/W2907684934","https://openalex.org/W2987108645"],"abstract_inverted_index":{"Introduction:":[0],"The":[1,349,461,473,487,540,574],"approval":[2,66],"of":[3,14,23,45,67,89,105,219,248,271,365,398,490,543,596,636,674,790],"several":[4],"new,":[5],"targeted":[6,565],"agents":[7,47],"has":[8],"been":[9],"transformative":[10],"in":[11,27,71,77,108,152,340,570,629,653],"the":[12,21,42,63,90,192,216,279,400,507,512,549,634,672],"treatment":[13,363],"CLL.":[15,112],"Prospective":[16],"clinical":[17,650],"trial":[18],"data":[19,38,172,644],"support":[20],"use":[22],"Ven":[24,68,127,223,272,337,355,371,442,547],"after":[25,591,676,693],"Ibr":[26,106,143,189,445,454,466,491,505,519,554,579,619,647,675,682],"CLL":[28,186,657,690],"(Jones":[29],"JA":[30],"et":[31,50,58],"al.":[32,51,59],"Lancet":[33],"Oncol":[34],"2018);":[35],"however,":[36],"limited":[37],"are":[39,667],"available":[40,181],"on":[41,354,477,504,786],"inverse":[43],"sequencing":[44,87],"these":[46,643],"(Mato":[48],"AR":[49],"Br":[52],"J":[53],"Haematol":[54],"2018;":[55],"Anderson":[56],"M":[57],"Blood":[60],"2017).":[61],"Given":[62],"recent":[64],"FDA":[65],"+":[69],"obinutuzumab":[70],"first-line":[72],"(1L)":[73],"CLL,":[74,124],"an":[75,787],"upsurge":[76],"Ibr-na\u00efve":[78,109,123],"pts":[79,110,121,151,184,289,298,308,324,410,517,551,562,576,688],"needing":[80],"therapy":[81,145,209,249,492,514,680],"post-Ven":[82,190,456,652],"is":[83,88],"likely;":[84],"characterizing":[85],"this":[86],"upmost":[91],"importance.":[92],"Here":[93],"we":[94],"present":[95],"a":[96,291,361,417,637,684,706],"US":[97],"multicentre,":[98],"retrospective,":[99],"chart-review":[100],"analysis":[101],"to":[102,195,207,222,269,336,352,373,396,444,453,465,475,483,546,556,581,623,669,769],"explore":[103],"outcomes":[104,117],"post-Ven,":[107,479],"with":[111,122,126,185,360,681,689],"Methods:":[113],"Efficacy":[114],"and":[115,141,164,215,231,254,321,343,381,413,434,497,535,593,614,625],"safety":[116,661,719,727],"were":[118,158,180,229],"investigated":[119],"for":[120,182,501,548,687],"treated":[125,159],"+/-":[128],"CD20":[129,147,262],"monoclonal":[130],"antibody":[131],"(mAb),":[132],"who":[133,187,552,577,691],"developed":[134],"progressive":[135],"disease":[136],"([PD]":[137],"or":[138,154,259,261,330,334,589,792],"discontinued":[139,370,518,553,578],"Ven)":[140],"received":[142,188,245,257,563],"salvage":[144,679],"(+/-":[146],"mAb).":[148],"Analyses":[149],"included":[150],"1L":[153],"relapsed/refractory":[155],"setting.":[156],"Pts":[157,369],"between":[160],"Feb":[161],"14,":[162],"2012":[163],"Jun":[165],"6,":[166],"2019,":[167],"across":[168],"four":[169],"institutions":[170],"(US);":[171],"cutoff":[173],"was":[174,199,210,224,273,283,338,356,404,447,457,467,493,558],"Jul":[175],"18,":[176],"2019.":[177],"Results:":[178],"Data":[179,718,726],"27":[183],"-":[191,892],"largest":[193],"cohort":[194],"date.":[196],"Median":[197,265,439],"age":[198],"64":[200],"(41-79)":[201],"years,":[202],"median":[203,217,280,350,362,401,451,488,508,513,541],"time":[204,266,351,440,452,474,510],"from":[205,267,441,481],"diagnosis":[206,268],"first":[208],"9.0":[211],"(0-117.7)":[212],"months":[213],"(mo),":[214],"number":[218,542],"therapies":[220,228,544],"prior":[221,545],"2":[225,559,575],"(0-9).":[226],"Prior":[227,395],"varied":[230,480],"included:":[232,424],"1":[233,243,571,630],"Bruton's":[234],"tyrosine":[235],"kinase":[236],"inhibitor":[237],"(BTKi;":[238],"not":[239,392],"Ibr),":[240],"3":[241],"lenalidomide,":[242,252],"pt":[244,572],"9":[246,550],"lines":[247],"(including:":[250],"idelalisib,":[251],"anti-CD22":[253],"temsirolimus),":[255],"others":[256],"chemo-":[258],"chemoimmunotherapy,":[260],"mAb":[263],"only.":[264],"initiation":[270,397,443,446,455],"56.3":[274],"(0-157.7)":[275],"mo.":[276,368,460],"At":[277],"baseline,":[278],"lymphocyte":[281,402],"count":[282,403],"2.2":[284],"(0.2-220.0)":[285],"K/\u00b5L;":[286,407],"8/24":[287],"(33.3%)":[288],"had":[290,300,309,313,317,325,411,416,648],"lymph":[292,418],"node":[293,419],"\u2265":[294,420],"5cm.":[295,421],"All":[296],"evaluable":[297,346,393],"(26/26)":[299],"\u22651":[301],"unfavourable":[302],"prognostic":[303],"risk":[304],"factor;":[305],"12/20":[306],"(60.0%)":[307],"del17p,":[310],"10/16":[311],"(62.5%)":[312],"del11q,":[314],"12/24":[315],"(50.0%)":[316],"complex":[318],"karyotype":[319],"(CK)":[320],"13/15":[322],"(86.7%)":[323],"unmutated":[326,435],"IGHV.":[327],"A":[328],"complete":[329],"partial":[331],"response":[332,463],"(CR":[333],"PR)":[335],"achieved":[339],"4/26":[341],"(15.4%)":[342],"18/26":[344],"(69.2%)":[345],"pts,":[347],"respectively.":[348,598],"PD":[353,374,522,557],"29.0":[357],"(1.0-118.0)":[358],"mo,":[359],"duration":[364,489],"18.0":[366],"(0.1-64.3)":[367],"due":[372,520,555,580,622],"(n=18),":[375],"consent":[376],"withdrawal":[377],"(n=2),":[378,532,607,613],"non-compliance":[379],"(n=1),":[380,605,609,611],"other":[382,615],"(n=6;":[383],"allogeneic":[384],"stem":[385],"cell":[386],"transplantation":[387],"n=2,":[388],"physician":[389,524],"decision":[390,525],"n=3,":[391],"n=1).":[394],"Ibr,":[399,478,597],"1.9":[405],"(0.01-179.0)":[406],"15/26":[408],"(57.7%)":[409],"adenopathy,":[412],"5/13":[414],"(38.5%)":[415],"Risk":[422],"factors":[423],"del17p":[425],"(4/10;":[426],"40.0%),":[427],"del11q":[428],"(4/9;":[429],"44.4%),":[430],"CK":[431],"(8/17;":[432],"47.1%)":[433],"IGHV":[436],"(11/14;":[437],"78.6%).":[438],"31.9":[448],"(1.8-60.3)":[449],"mo;":[450],"0.7":[458],"(0-39.7)":[459],"overall":[462],"rate":[464],"56.0%":[468],"(CR:":[469],"1/25,":[470],"PR:":[471],"13/25).":[472],"progression":[476],"3.0":[482],"53.0":[484],"mo":[485,496,500,595],"(n=10).":[486],"18.3":[494],"(3.7-53.2)":[495],"20.0":[498],"(4.9-44.3)":[499],"those":[502],"remaining":[503],"(8/27);":[506],"follow-up":[509],"matched":[511],"duration.":[515],"Nineteen":[516],"to:":[521],"(n=9),":[523],"(n=4),":[526],"adverse":[527],"events":[528],"(AEs;":[529],"n=2),":[530],"transplant":[531],"symptomatic":[533],"deterioration":[534],"unknown":[536],"reason":[537],"(n=1":[538],"each).":[539],"(1-9);":[560],"4/9":[561],"novel":[564],"therapies.":[566],"Richter's":[567],"transformation":[568],"occurred":[569,628],"(1/9).":[573],"AEs":[582,601],"experienced":[583],"either":[584],"atrial":[585],"fibrillation":[586],"(AF)/brain":[587],"abscess":[588],"pneumonia":[590],"11.6":[592],"18.2":[594],"Other":[599],"notable":[600],"were:":[602],"major":[603],"bleeding":[604],"AF":[606],"infection":[608],"neutropenia":[610],"myalgia/arthralgia":[612],"cardiac":[616],"event":[617],"(n=1).":[618],"dose":[620],"reductions":[621],"fatigue":[624],"general":[626],"malaise":[627],"pt.":[631],"Conclusions:":[632],"With":[633],"limitations":[635],"retrospective":[638],"series":[639],"using":[640],"real-world":[641],"data,":[642],"suggest":[645],"that":[646],"substantial":[649],"activity":[651],"heavily":[654],"pre-treated,":[655],"high-risk":[656],"pts;":[658],"no":[659],"new":[660],"signals":[662],"arose.":[663],"Larger,":[664],"prospective":[665],"studies":[666],"required":[668],"fully":[670],"characterize":[671],"efficacy":[673],"Ven.":[677,694],"Meanwhile,":[678],"remains":[683],"good":[685],"option":[686],"relapse":[692],"Disclosures":[695],"Brown:":[696],"Sunesis:":[697,923],"Consultancy;":[698,700,702,704,723,734,742,748,751,753,756,758,760,763,804,831,842,847],"Pharmacyclics:":[699,871],"Pfizer:":[701],"Novartis:":[703,862],"Kite,":[705],"Gilead":[707,779,912],"Company:":[708],"Consultancy,":[709,713,744,765,850,859,872],"Research":[710,714,739,745,766,818,821,824,828,833,836,839,844,851,856,863,866,869,873,907,910,914,918,921,924,927,931,934,938,941,946,951,954,959],"Funding;":[711,715,740,746,822,825,834,837,840,845,857,864,867,870,908,911,915,919,922,925,928,932,935,939,942,947,952,955],"Loxo:":[712],"Invectys:":[716],"Other:":[717,725],"monitoring":[720,728],"board;":[721,729],"Octapharma:":[722],"Morphosys:":[724],"Janssen:":[730,858],"Honoraria;":[731,736,771],"Dynamo":[732],"Therapeutics:":[733,750,762,937],"Teva:":[735],"Sun":[737],"Pharmaceuticals:":[738],"Genentech/Roche:":[741],"Gilead:":[743,855,899],"BeiGene:":[747],"Catapult":[749],"AstraZeneca:":[752],"Acerta":[754,773,805,956],"Pharma:":[755],"AbbVie:":[757,926],"Juno/Celgene:":[759],"TG":[761,783,815],"Verastem:":[764,803,817],"Funding.":[767,819,829,960],"Davids:Research":[768],"Practice:":[770],"AbbVie,":[772,795],"Pharma,":[774,806,808],"Adaptive,":[775],"Biotechnologies,":[776],"Astra-Zeneca,":[777,796],"Genentech,":[778,797,809],"Sciences,":[780],"Janssen,":[781,798],"Pharmacyclics,":[782,800,812],"therapeutics:":[784],"Membership":[785],"entity's":[788],"Board":[789],"Directors":[791],"advisory":[793],"committees;":[794],"MEI,":[799],"Syros":[801],"Pharmaceuticals,":[802],"Ascentage":[807],"MEI":[810],"pharma,":[811],"Surface":[813],"Oncology,":[814],"Therapeutics,":[816],"Chang:Genentech:":[820],"Celgene:":[823],"Adaptive":[826],"Biotechnologies:":[827],"Ma:Kite:":[830],"Xeme:":[832],"Abbvie:":[835],"Beigene:":[838],"Bioverativ:":[841],"Incyte:":[843],"Genentech:":[846,953],"Astra":[848],"Zeneca:":[849],"Funding,":[852,874],"Speakers":[853,860,875],"Bureau;":[854,861],"Juno:":[865],"Acerta:":[868],"Bureau.":[876],"Biondo:Genentech,":[877],"Inc.:":[878,945,950],"Employment;":[879],"F.":[880],"Hoffmann-La":[881],"Roche":[882,894],"Ltd:":[883,895,903],"Equity":[884,888,897,900,904],"Ownership.":[885,889,905],"Mun:Genentech:":[886],"Employment,":[887,896],"Breuleux:F.":[890],"Hoffmann":[891],"La":[893],"Ownership;":[898,901],"Basilea":[902],"Wierda:Janssen:":[906],"Xencor:":[909],"Sciences:":[913],"Pharmacyclics":[916],"LLC:":[917],"Cyclcel:":[920],"KITE":[929],"pharma:":[930],"Miragen:":[933],"Juno":[936],"GSK/Novartis:":[940],"Oncternal":[943],"Therapeutics":[944],"Loxo":[948],"Oncology":[949],"Pharma":[957],"Inc:":[958]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-11-22T00:00:00"}